Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome

Hepatology

Volumn 48, Issue 2, 2008, Pages 686-

  Kalambokis, Georgios N ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MIDODRINE; TERLIPRESSIN; VASOCONSTRICTOR AGENT;

ASCITES; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEPATORENAL SYNDROME; HUMAN; LETTER; LIVER CIRRHOSIS; LIVER CIRRHOTIC ASCITES; NATRIURESIS; NON HEPATORENAL SYNDROME; PRIORITY JOURNAL; REFRACTORY ASCITES; SPLANCHNIC BLOOD FLOW;

ADRENERGIC ALPHA-AGONISTS; ASCITES; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LYSINE VASOPRESSIN; MIDODRINE; VASOCONSTRICTOR AGENTS;

EID: 49649086417     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22247     Document Type: Letter

References (13)

1. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-221.
2. Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Kacsaraki A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005;100:879-885.
3. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. HEPATOLOGY 1998;28:937-943.
4. Zanditenas D, Condat B, Blazquez M, Bonnet J, Mavier JP, Mallat A, et al. Effects of prolonged administration of midodrine in the treatment of diuretic resistant ascites: A pilot study [Abstract]. HEPATOLOGY 2007; 46(Suppl):251A.
5. Tsuchida K, Yamazaki R, Kaneko K, Aihara H. Effects of midodrine on blood flow in dog vascular beds. Arzneimittelforschung 1986;36:1745-1748.
6. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
7. Krag A, Moller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. HEPATOLOGY 2007;46:1863-1871.
8. Gadano A, Moreau R, Vachiery F, Soupison T, Yang S, Cailmail S, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997; 26:1229-1234.
9. Kalambokis G, Economou M, Kosta P, Papadimitriou P, Pappas C, Katsaraki A, et al. Effects of somatostatin, terlipressin, and somatostatin plus terlipressin on portal and systemic hemodynamics, and renal sodium excretion in patients with cirrhosis. J Gastroenterol Hepatol 2005;20:1075-1081.
10. Therapondos G, Stanley AJ, Hayes PC. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: A pilot study. J Gastroenterol Hepatol 2004;19:73-77.
11. Alessandria C, Debernardi-Venon W, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: Role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368.
12. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-48.
13. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: Type 1 HRS and beyond. HEPATOLOGY 2006;43:385-394.